Revolutionizing Weight Loss: Eli Lilly's Oral Pill Offers Hope for Long-Term Maintenance
Obesity is a chronic, progressive disease, and sustaining weight loss remains a significant challenge for many. But what if there was a simpler, more accessible way to maintain weight loss without the hassle of weekly injections? That's the promise of Eli Lilly's new oral pill, orforglipron, which has shown promising results in a late-stage trial.
The trial, called ATTAIN-MAINTAIN, followed over 300 patients with obesity who previously took Wegovy or Zepbound for 72 weeks. These patients were then randomized to take either Eli Lilly's pill or a placebo for another 52 weeks. The results were impressive: patients who switched to the pill from Wegovy only regained around 2 pounds of the weight they initially lost, while those who switched from Zepbound regained only about 11 pounds.
This is a significant improvement over the existing injections, which many people struggle to maintain long-term. The oral pill appears to cause less weight loss overall, but its potential role as a needle-free maintenance treatment in the blockbuster GLP-1 market is undeniable. However, an oral pill for obesity from Novo Nordisk will likely enter the market first, giving the Danish drugmaker a head start in staking its claim in the space.
The pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk's diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person's appetite and regulate blood sugar. Unlike these three treatments, Eli Lilly's pill is not a peptide medication, which means it is absorbed more easily by the body and does not require dietary restrictions.
While the overall safety and tolerability of the pill were consistent with previous late-stage studies, the most common side effects were gastrointestinal-related and generally mild-to-moderate in severity. Around 4.8% of people who switched to the pill from Wegovy discontinued treatment due to side effects, while 7.2% of those who switched to the oral drug from Zepbound did the same. However, these rates were lower than those who switched to a placebo from Wegovy and Zepbound, respectively.
The positive trial data suggest that the pill could be an effective treatment for patients who want to preserve their weight loss but don't want to take weekly injections long-term. Many people who stop those shots regain much of the weight they initially shed. Eli Lilly's pill offers hope for a simpler, more accessible way to maintain weight loss, and could provide a convenient alternative for the millions of individuals living with obesity around the globe.
